3rd floor Kalpataru Inspire,
Off. W E Highway, Santacruz (East),
Mumbai 400055. India
The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life. Embedded in Lupin was a formula for growth. Forty six years on, what has stayed with us is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people. We are today a fully integrated pharmaceutical company with an unrivaled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. We are Built to Grow.
HEADQUARTERED IN MUMBAI, INDIA, LUPIN LIMITED TODAY IS AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY PRODUCING A WIDE RANGE OF QUALITY, AFFORDABLE GENERIC AND BRANDED FORMULATIONS AND APIs FOR THE DEVELOPED AND DEVELOPING MARKETS OF THE WORLD.
Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally. Lupin first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. segments.
GLOBAL FORMULATIONS BUSINESS:
India is a critical part of Lupin’s ambitious growth plans and contributed 24% to the Company’s global revenues. Emerging from the shadows of a tumultuous FY 2014 where the entire industry and the Indian Pharmaceutical Market (IPM) were adversely affected by changes in the Drug Price Control Order (DPCO), Lupin’s domestic formulations business emerged stronger in FY 2015, clocking in revenues of 30,295 million, a growth of 20.5% over the previous year, outpacing and outperforming the IPM which grew by 12.1% (IMS MAT, March 2015).
This translates into a CAGR of 18% for the last 4 years. Chronic therapies contributed 66% of India revenues in FY 2015 (44% in FY 2008). Our performance is also a reflection of our ability to combat and respond to an intensely competitive, fragmented and dynamic business environment; testimony to the commitment and passion of our 5500+ medical sales & marketing team. Our flawless execution that has made us a key player in fast growing therapies such as Cardiology, Central Nervous System (CNS), Diabetes, Anti-Asthma, COPD, Gastro- intestinal (GI) and Gynaecology. We continue to be the market leader in the Anti-TB market and are the 3rd largest player in Cardiology and Anti- Asthma segments. We grew our market share in therapies such as Diabetology on the back of new product launches. A marked improvement from being the 7th largest player in FY 2014. The Company has been constantly fine tuning its product portfolio by adding innovative new products, which explains why Lupin has one of the fastest growing and largest portfolios of young high growth brands. We now have 26 brands with sales upwards of 300 million, 4 out of which have sales exceeding 1,000 million (Gluconorm, Huminsulin, Tonact and Rablet).
Our existing associations with global think tanks and institutions like American College of Cardiology (ACC), American College of Chest Physicians (ACCP); the Ian Donald School; the European Society of Cardiology (ESC); the European Society of Cardiology – Heart Failure Association (ESC HFA) and European Association for Neurological Societies (EANS) to name a few have gone a long way in bringing the latest technical know-how and advances to the medical community within the IPM. Spreading awareness, patient education and meaningful care has always been a key focus for the Company and we continue to educate patients and society at large on diagnosis and preventive care across the country, be it our Spirometry and CO monitoring camps which have helped diagnose Asthma / COPD; BMD Camps for detection of osteoporosis and related disorders; or the special Diabetes (HB1AC) camps and hypertension & lipid profile campaigns that we have conducted.
CORPORATE SOCIAL OBLIGATION:
MUCH OF WHAT HAPPENS IN OUR WORLD IS THE RESULT OF HOW WE THINK, FEEL AND ACT – ABOUT OTHERS AND ABOUT OURSELVES. WHEN YOU PUT YOUR FAITH IN PEOPLE, SHARE WHAT YOU HAVE LEARNT AND GIVE FREELY, THEN GOOD THINGS BEGIN TO HAPPEN – BELIEF, SHARING, OWNERSHIP, GROWTH, JOY AND SO MUCH MORE. WHEN PEOPLE TAKE CARE OF EACH OTHER, THEY CONNECT, THEY EXIST, FLOURISH AND COMMUNITIES GROW.
Progress and self-development are levers to achieve the outcomes we seek in the world – individually and collectively. Yes, I Believe–Dr. Desh Bandhu Gupta (DBG), Founder & Chairman, Lupin Limited.
The LHWRF mission is simple, to ensure that we uplift families living below the poverty line in our rural hinterland.
“To Believe” was the simple thought that was in DBG’s mind when he set up the Lupin Human Welfare and Research Foundation (LHWRF) in 1988. He in his own way rephrased the moral and ethical role that business could play in society; he believes it is his duty and his responsibility.
MISSION: To provide an alternative model of rural development that is sustainable, replicable and ever-evolving; to empower the underprivileged and marginalized sections of society.
VISION: To see Indian villages not only develop economically, but flourish as centers of prosperity and progress
KEY INITIATIVES AND ACCOMPLISHMENTS: These include initiatives in increasing agricultural yields, animal husbandry, skill development & enterprise building, women empowerment, healthcare, literacy, education, rural infrastructure and natural resources management.
Life At Lupin:
Welcome to one of the most exciting growth stories in the pharmaceutical industry. At the very heart of Lupin and our phenomenal growth story is our biggest asset – Our People. We are proud of their passion and commitment to the company and the alignment of their aspirations and dreams to our shared vision. Our growth and successes are met equally by even greater steps to ensure that we not only comply but lead in areas of processes and human relations to unleash and harness innovation at every level within the organization. It is the behavior of our leadership team and our people, their shared wisdom, which has gone into creating the business democracy that is Lupin – a Company where entrepreneurship and innovation thrive. As a closely knit team of over 15000 Lupinytts globally, we have outperformed the Industry over the last 7 years. It is against this backdrop that the Human Resources (HR) assumes a strategic and critical role. HR at Lupin has gone beyond traditional employee engagement programs to ensure that Lupin not only nurtures talent and leadership internally, but also develops platforms that help identify potential talent by creating opportunities to learn, perform and succeed. Innovative Platforms & Programs that makes Lupin amongst the best to place to work within the pharmaceutical and biotechnology industry.
Krebs Biochemicals & Industries Limited
click above to visit
this company / organization